Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics

BMY POWR Grades

• Value is the dimension where BMY ranks best; there it ranks ahead of 97.66% of US stocks.
• The strongest trend for BMY is in Growth, which has been heading down over the past 179 days.
• BMY's current lowest rank is in the Momentum metric (where it is better than 4.61% of US stocks).

BMY Stock Summary

• With a market capitalization of $155,571,152,590, BRISTOL MYERS SQUIBB CO has a greater market value than 98.77% of US stocks.
• Over the past twelve months, BMY has reported earnings growth of -281.92%, putting it ahead of just 5.61% of US stocks in our set.
• In terms of volatility of its share price, BMY is more volatile than only 2% of stocks we're observing.
• Stocks with similar financial metrics, market capitalization, and price volatility to BRISTOL MYERS SQUIBB CO are SNY, RTX, DE, NVS, and GILD.
• Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.

BMY Valuation Summary

• In comparison to the median Healthcare stock, BMY's price/earnings ratio is 3.96% higher, now standing at 23.6.
• BMY's price/sales ratio has moved up 0.9 over the prior 243 months.

Below are key valuation metrics over time for BMY.

BMY Growth Metrics

Its 5 year revenue growth rate is now at 55.3%.
• The 4 year revenue growth rate now stands at 55.3%.
• The 5 year net cashflow from operations growth rate now stands at 158.02%.

Over the past 67 months, BMY's revenue has gone up $26,773,000,000.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	46,738	13,817	6,677
2022-06-30	47,144	15,396	6,617
2022-03-31	46,960	16,195	6,251
2021-12-31	46,385	16,207	6,994
2021-09-30	45,468	15,820	-5,405
2021-06-30	44,384	12,773	-5,079

BMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BMY has a Quality Grade of B, ranking ahead of 79.64% of graded US stocks.
• BMY's asset turnover comes in at 0.38 -- ranking 124th of 680 Pharmaceutical Products stocks.
• PAHC, ACUR, and XLRN are the stocks whose asset turnover ratios are most correlated with BMY.

The table below shows BMY's key quality metrics over time.